Affordable Access

deepdyve-link
Publisher Website

Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation.

Authors
  • Blondel, S1, 2
  • Egesipe, A-L3
  • Picardi, P4
  • Jaskowiak, A-L3
  • Notarnicola, M5
  • Ragot, J1, 2
  • Tournois, J3
  • Le Corf, A1, 2
  • Brinon, B3
  • Poydenot, P3
  • Georges, P3
  • Navarro, C6, 7
  • Pitrez, P R8
  • Ferreira, L8
  • Bollot, G9
  • Bauvais, C9
  • Laustriat, D3
  • Mejat, A10
  • De Sandre-Giovannoli, A6, 7
  • Levy, N6, 7
  • And 4 more
Type
Published Article
Journal
Cell Death and Disease
Publisher
Springer Nature
Publication Date
Feb 18, 2016
Volume
7
Identifiers
DOI: 10.1038/cddis.2015.374
PMID: 26890144
Source
Medline
License
Unknown

Abstract

Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by a dramatic appearance of premature aging. HGPS is due to a single-base substitution in exon 11 of the LMNA gene (c.1824C>T) leading to the production of a toxic form of the prelamin A protein called progerin. Because farnesylation process had been shown to control progerin toxicity, in this study we have developed a screening method permitting to identify new pharmacological inhibitors of farnesylation. For this, we have used the unique potential of pluripotent stem cells to have access to an unlimited and relevant biological resource and test 21,608 small molecules. This study identified several compounds, called monoaminopyrimidines, which target two key enzymes of the farnesylation process, farnesyl pyrophosphate synthase and farnesyl transferase, and rescue in vitro phenotypes associated with HGPS. Our results opens up new therapeutic possibilities for the treatment of HGPS by identifying a new family of protein farnesylation inhibitors, and which may also be applicable to cancers and diseases associated with mutations that involve farnesylated proteins.

Report this publication

Statistics

Seen <100 times